Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831397 | 1.00 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL4451613 | 0.93 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL7553293 | 0.93 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL3721728 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL20828930 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19549038 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6284695 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19709160 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6284697 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL19709158 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2000055179-A1 | NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-6121437-A | SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | TYMP 1/4885P2RY14 586/4885P2RY2 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.